Avastin

Avastin
Name	Avastin
Drug class	Monoclonal antibody
Routes of administration	Intravenous infusion
ATC prefix	L01
ATC suffix	XC07

Avastin. It is a monoclonal antibody medication designed to inhibit angiogenesis, the process of new blood vessel formation, by targeting vascular endothelial growth factor A (VEGF-A). Developed by the biotechnology company Genentech, it was first approved by the U.S. Food and Drug Administration in 2004 for the treatment of metastatic colorectal cancer. Its introduction marked a significant advance in oncology, utilizing an anti-angiogenic mechanism to starve tumors of their blood supply.

Medical uses

Avastin is indicated, in combination with various chemotherapy regimens, for the treatment of several advanced cancers. These include metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and cervical cancer. It is also used in ophthalmology off-label for neovascular age-related macular degeneration, though this use is distinct from its FDA-approved oncology indications. Treatment protocols are typically administered via intravenous infusion in clinical settings such as hospitals or specialized oncology clinics.

Mechanism of action

The drug functions as a recombinant humanized monoclonal antibody that specifically binds to vascular endothelial growth factor A (VEGF-A). By binding to VEGF-A, Avastin prevents this protein from interacting with its receptors, VEGFR-1 and VEGFR-2, on the surface of endothelial cells. This blockade inhibits the VEGF signaling pathway, a critical driver of angiogenesis. Consequently, the formation of new blood vessels within tumors is suppressed, which can limit tumor growth and the potential for metastasis.

Adverse effects

Treatment with Avastin is associated with a range of potentially serious side effects related to its inhibition of normal angiogenesis. Common adverse events include hypertension, proteinuria, and impaired wound healing. More severe risks include gastrointestinal perforation, severe hemorrhage such as pulmonary hemorrhage, and events related to arterial thromboembolism like myocardial infarction or stroke. The European Medicines Agency and other regulatory bodies mandate strict monitoring for these effects during therapy.

Clinical trials

The pivotal clinical evidence for Avastin came from studies like the AVF2107g trial in colorectal cancer, which demonstrated improved overall survival. Subsequent major trials include ECOG 4599 in non-small cell lung cancer and the AVAGAST trial in gastric cancer. While many studies, such as those in breast cancer (e.g., E2100), showed initial promise, subsequent analyses led the FDA to revoke its approval for that indication. Research continues through organizations like the National Cancer Institute to explore its efficacy in other malignancies.

Biosimilars and generics

Following the expiration of key patents held by Genentech and its parent company Roche, several biosimilar versions of Avastin have entered the global market. Regulatory agencies like the European Commission and the FDA have approved biosimilars from companies including Amgen (Mvasi), Pfizer, and Celltrion. These biosimilars undergo rigorous comparative analytical and clinical studies, such as trials in non-small cell lung cancer, to establish similarity in terms of safety, purity, and potency to the reference product.

Controversies and legal issues

The drug has been central to several controversies, notably the FDA's 2011 decision to revoke its approval for metastatic breast cancer following confirmatory trials that failed to verify clinical benefit. Significant legal and ethical debates have arisen from its off-label use in ophthalmology, particularly concerning cost and Medicare reimbursement, highlighted in cases like United States ex rel. Herbert v. National Institute of Health. Furthermore, Genentech has been involved in litigation over patent rights and pricing strategies with various stakeholders in the pharmaceutical industry.

Category:Monoclonal antibodies Category:Antineoplastic drugs Category:Genentech